Cui et al. demonstrated that SFN treatment as NRF activator increased renal Nrf2 expression, prevented diabetic nephropathy and thereby attenuated both oxidative damage and fibrosis in a diabetic mouse model [90]. Here, NFE2L2 is linked to diabetic kidney disease.